TUBINGEN, GERMANY / ACCESSWIRE / March 30, 2022 / HepaRegeniX GmbH, a clinical-stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver disease, today announced the appointment of Elias Papatheodorou as Chairman of the Board with executive duties. It follows Dr. Graham Dixon who has served as Chairman of the Board of HeparegeniX since 2017.
“We are delighted to welcome Elias as the new Chairman of the Board. With two decades of industry experience, he will greatly benefit HepaRegeniX with his strategic guidance and leadership. His knowledge of the biopharmaceutical industry , particularly business development, operations and capital markets as well as his track record of successful mergers and acquisitions and licensing deals, will contribute immensely to our financing and BD’s planning and transactions” , said Dr. Wolfgang Albrecht, Managing Director, COO and Co-Founder of HepaRegeniX . “We thank Graham for his valuable contributions as chairman over the past few years and wish him well with his new endeavours.”
“I am pleased to join the HepaRegeniX Board of Directors during these exciting times with the first clinical results to come and several assets in the pipeline,” added Elias Papatheodorou, Chairman of the HepaRegeniX Board of Directors . “Along with the team, I look forward to contributing to HepaRegeniX’s development strategy and successfully implementing our vision of providing urgent treatment options for critically ill liver patients by enabling regeneration after hepatectomy or degenerative liver disease.”
Elias Papatheodorou is currently the Independent Chairman of the Board of Memo Therapeutics and a member of the Board of Tribune Therapeutics. Elias Papatheodorou has over 20 years of C-level experience in the biotechnology industry, including marketing and sales, business development, mergers and acquisitions, and operations. Previously, he was CEO of Genkyotex, a clinical-stage fibrosis biopharmaceutical, acquired by Calliditas Therapeutics in 2021. Prior to serving as CBO of multispecies protein company Covagen, acquired by Janssen in 2014, and CEO of Novosom, a supplier d’RNA company acquired by Marina Biotech in 2010. He also served as Vice President and Senior Vice President at MediGene. Elias studied at Ithaca College, NY, and Cornell University, NY, USA.
For more information, please contact:
Dr Wolfgang Albrecht
Managing Director, COO
For media inquiries:
MC Services SA
Katja Arnold, Andreas Jungfer
+49 89 210 228-0
United Kingdom: Shaun Brown
M: +44 7867 515 918
About HepaRegeniX GmbH – www.heparegenix.com
Since 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target M Itogen-activated protein (MAP) K inase K inase 4 (MKK4). The first MKK4 inhibitor HRX-0215 recently completed phase 1 clinical trials. MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes, even in critically diseased livers. This new and unique therapeutic concept was discovered by Professor Lars Zender and his research group at the University Hospital in Tubingen, Germany. Investors in HepaRegeniX include Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
THE SOURCE: HepaRegeniX GmbH
See the source version on accesswire.com: